Clinical Trials Browser

Phase 1/2 × Lymphoma, Non-Hodgkin × Immunotherapy, Adoptive × Clear all

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03277729 2026-01-05

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04206943 2020-01-27

ISIKOK-19

Phase 1/2 Unknown

24 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02315118 2016-06-22

Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies

Phase 1/2 Unknown

18 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

ISIKOK-19

Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies